Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 2/20 | 0.37 |
| ▸ | XIAP | P98170 | 7/20 | 0.37 |
| ▸ | BIRC3 | Q13489 | 3/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTR1E | P28566 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284064 | 1.00 | BUB1 (0.37) | BUB1XIAPBIRC3BIRC2TSHR | |
| SCHEMBL15312668 | 0.87 | CTSL (0.34) | XIAPBIRC3BIRC2TSHRCTSV | |
| SCHEMBL2632156 | 0.86 | XIAP (0.30) | XIAPBIRC3BIRC2 | |
| SCHEMBL2117956 | 0.86 | XIAP (0.30) | XIAPBIRC3BIRC2 | |
| SCHEMBL17554686 | 0.85 | XIAP (0.36) | BUB1XIAPBIRC3BIRC2TSHR | |
| SCHEMBL2631855 | 0.82 | XIAP (0.53) | XIAPBIRC3BIRC2 | |
| SCHEMBL2631843 | 0.82 | XIAP (0.53) | XIAPBIRC3BIRC2 | |
| SCHEMBL13048215 | 0.81 | — | — | |
| SCHEMBL2117031 | 0.81 | HSD17B10 (0.39) | TSHRCTSLCTSSCTSKLMNA | |
| SCHEMBL2622149 | 0.81 | HSD17B10 (0.39) | TSHRCTSLCTSSCTSKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434889-B1 | IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | BUB1 1650/4885XIAP 1/4885BIRC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.